

AION Therapeutic Inc.

11:00 22 Feb 2021

Aion Therapeutic: Meet the team using artificial intelligence to create a full lineup of psychedelic and cannabis therapies

Aion Therapeutic Inc (CSE:AION), Lobe Sciences Ltd (CSE:LOBE) (OTCMKTS: (GTSIF) and Silo Pharma Inc (OTCMKTS:SILO) are presenting at Proactive's next virtual showcase event on February 23.

The psychedelic-themed event will be hosted by Proactive's Christine Corrado and kicks off on Tuesday at 1 PM ET.

SIGN-UP: Proactive One2One February 23

Toronto-based Aion Therapeutic Inc (CSE:AION) recently filed five patent applications with the US Patent and Trademark Office related to the combination of medical cannabis with edible and psychedelic mushrooms.

The applications include formulations designed to treat a variety of conditions, including cancer, psychiatric disorders, addiction, viral diseases, obesity and inflammatory disorders.

Aion's combinatorial treatment formulation discovery platform relies on artificial intelligence (AI) techniques. By utilizing AI, the company plans to create a full line of therapeutic products that includes combinatorial pharmaceuticals, nutraceuticals and cosmeceuticals, as well as individualized treatments for personalized medicine using human genome and other data.

Executive chairman Dr Stephen Barnhill will take participants through the firm's pharmaceutical research and product development. Aion also operations in Jamaica, where psychedelics are more available.

"Jamaica provides Aion Therapeutic an incredibly unique opportunity in that it is one of the very few countries in the world where mushrooms have never been made illegal and are openly sold," Barnhill said recently.

"It is worth noting that Aion Therapeutic has this incredible research and development opportunity through our partnership with Apollon Formularies Jamaica Ltd, a CLA-licensed medical cannabis company," Barnhill added. "This partnership allows Aion Therapeutic to legally discover these unique medical cannabis and medical mushroom combinations for therapeutic product formulations. We believe that we can build a large portfolio of blocking patents while most of the rest of the world faces legal hurdles that limit efforts in this type of research and discovery."

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Price: 0.125

Market Cap: \$12.84 m

1 Year Share Price Graph



Share Information

Code: AION

Listing: CSE

52 week	High	Low
	0.19	0.06

Sector: Cannabis

Website: www.aiontherapeutic.com

Company Synopsis:

Aion Therapeutic Inc. operates as a pharmaceutical company. The Company focuses on creating novel patent protected therapeutic formulations using medical cannabis for the treatment of patients with many types of illnesses including cancer, psychiatric disorders, addiction, viral infections, obesity, and chronic inflammation. Aion Therapeutic serves customers in Canada.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of AION Therapeutic Inc. named herein, including the promotion by the Company of AION Therapeutic Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).